Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXIOMATIC-TKR: Milvexian vs Enoxaparin in Total Knee Replacement
NCT03891524Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised, open-label trial of milvexian in venous thromboembolism (VTE) (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants With Total Venous Thromboembolism (VTE). Started Jun 2019; status: completed.
02
Drugs
milvexian
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03891524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891524.